Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859531 | 0.91 | NTRK1 (0.40) | GABRA5PAK4STAT3HRH3PRKAA2 | |
| SCHEMBL17844705 | 0.89 | GABRA5 (0.40) | GABRA5PAK4STAT3HRH3HPGD | |
| SCHEMBL17844730 | 0.85 | PAK4 (0.61) | GABRA5PAK4STAT3HRH3PRKAA2 | |
| SCHEMBL17844729 | 0.85 | PAK4 (0.61) | GABRA5PAK4STAT3HRH3PRKAA2 | |
| SCHEMBL19742269 | 0.83 | GABRA5 (0.41) | GABRA5PAK4STAT3HPGDHTR1A | |
| SCHEMBL17844699 | 0.82 | GABRA5 (0.39) | GABRA5PAK4STAT3HRH3HPGD | |
| SCHEMBL17844713 | 0.82 | PAK4 (0.43) | GABRA5PAK4STAT3HRH3PTK2 | |
| SCHEMBL17844722 | 0.82 | PAK4 (0.43) | GABRA5PAK4STAT3HRH3HPGD | |
| SCHEMBL16345134 | 0.82 | PAK4 (0.56) | GABRA5PAK4STAT3HRH3 | |
| SCHEMBL19753594 | 0.80 | GABRA5 (0.44) | GABRA5PAK4STAT3HRH3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
| WO-2016100515-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | MALT1, BCL9, BCL6 | GABRA5 2240/4885PAK4 1077/4885STAT3 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.